Literature DB >> 35241455

Molnupiravir's authorisation was premature.

James M Brophy1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35241455     DOI： 10.1136/bmj.o443

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

Review 1.  Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with Epilepsy.

Authors:  Maor Wanounou; Yoseph Caraco; René H Levy; Meir Bialer; Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2022-07-27       Impact factor: 5.577

2.  Oral antiviral treatments for COVID-19: opportunities and challenges.

Authors:  Laila Rahmah; Sunny O Abarikwu; Amanuel Godana Arero; Mickael Essouma; Aliyu Tijani Jibril; Andrzej Fal; Robert Flisiak; Rangarirai Makuku; Leander Marquez; Kawthar Mohamed; Lamin Ndow; Dorota Zarębska-Michaluk; Nima Rezaei; Piotr Rzymski
Journal:  Pharmacol Rep       Date:  2022-07-25       Impact factor: 3.919

3.  Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.

Authors:  Carlos K H Wong; Ivan C H Au; Kristy T K Lau; Eric H Y Lau; Benjamin J Cowling; Gabriel M Leung
Journal:  Lancet Infect Dis       Date:  2022-08-24       Impact factor: 71.421

4.  Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study.

Authors:  Rujipas Sirijatuphat; Weerawat Manosuthi; Suvimol Niyomnaitham; Andrew Owen; Katherine Kradangna Copeland; Lantharita Charoenpong; Manoch Rattanasompattikul; Surakameth Mahasirimongkol; Nuanjun Wichukchinda; Kulkanya Chokephaibulkit
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.